First German Hospital Pilots Steriwave

Ondine Biomedical Inc.

22 December 2025

 

22 December 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

First German Hospital Pilots Steriwave

Ondine Biomedical Partners with LMU University Hospital Munich
 to Trial Steriwave in ENT Patients

Ondine Biomedical Inc. (AIM: OBI) is pleased to announce a significant research collaboration with LMU University Hospital Munich, one of Europe's most esteemed and highly ranked medical institutions. This partnership marks a pivotal step in introducing Ondine's Steriwave® photodisinfection technology to Germany, the European Union, and other major international markets, underscoring the growing importance of innovative infection prevention solutions in global healthcare.

The collaborative research initiative will be led by Professor Dr. Ronald Sroka, Head of the LIFE Center and Laser Research Laboratory at LMU University Hospital Munich, along with PD Dr. Veronika Volgger, Clinical Scientist at LIFE Center and Department of ENT at LMU University Hospital Munich. Renowned for its excellence in biophotonics and photodynamic therapy (PDT), the LIFE Center brings unparalleled expertise to this project, further strengthening the scientific foundation for Steriwave's clinical evaluation in ENT patients.

This initiative is bolstered by external clinical evidence, including a pilot study presented at the American Rhinologic Society's 66th Annual Meeting in 2020 by Prof. Claire Hopkins, consultant ENT surgeon at Guy's & St Thomas Hospital and London Bridge Hospital, and her team. Their findings demonstrated that routine pre-operative nasal photodisinfection significantly reduced the need for post-operative antibiotics in sinonasal surgery patients, with prescription rates dropping from 22.5% to 5% (P=0.02), highlighting the technology's potential to combat healthcare-associated infections and antimicrobial resistance.

Professor Dr. Ronald Sroka commented:

"Innovative solutions are more vital than ever in the fight against antibiotic resistance. Our team at LMU is deeply committed to advancing photodynamic approaches that address the growing threat of antimicrobial resistance. Ondine's Steriwave represents a promising, non-antibiotic strategy to reduce multidrug-resistant infections, and we are delighted to bring our clinical expertise to validate this important technology and help reduce unnecessary post-surgical infections."

Carolyn Cross, CEO of Ondine Biomedical Inc., stated:

"We are truly honoured to partner with the outstanding and visionary team at LMU University Hospital Munich. Their leadership in photodynamic therapy and commitment to scientific excellence make them the ideal collaborators as we introduce our innovative photodisinfection technology to Germany, the EU, and key global markets. This collaboration reflects our shared dedication to combating antibiotic resistance and delivering safe, effective infection prevention solutions that can transform patient care and outcomes worldwide."

About the LMU Hospital

The LMU University Hospital Munich (LMU Klinikum) is a leading institution in European medicine. In conjunction with the medical faculty of the esteemed Ludwig-Maximilians-Universität München, it constitutes one of the largest university hospitals in Germany and maintains significant influence throughout Europe. Regularly ranked among the Top 3-4 hospitals in Germany and within the Top 30 globally by Newsweek/Statista, LMU Klinikum delivers exemplary patient care, serving more than 500,000 patients each year across its two principal campuses.

About Steriwave^® Nasal Photodisinfection

Steriwave is CE-marked for nasal decolonisation. The treatment involves applying the proprietary Steriwave photosensitive agent to each nostril followed by illumination with a specific wavelength of red light. When used per the instructions for use, evidence demonstrates rapid reduction of nasal pathogens.

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies ('photodisinfection') for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.

Ondine's nasal photodisinfection system is CE-marked in Europe and is approved for nasal decolonisation in Canada, Australia, Mexico and several other countries under the name Steriwave^®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.

Enquiries:

Ondine Biomedical Inc.	www.ondinebio.com
Carolyn Cross, CEO	[phone] or via Vane Percy & Roberts
Strand Hanson Limited (Nominated & Joint Financial Adviser)
James Harris, Richard Johnson	[phone]
Peel Hunt LLP (Broker & Joint Financial Adviser)
James Steel, Dr. Chris Golden	[phone]
Vane Percy & Roberts (Media Contact)
Simon Vane Percy	[phone]

FOR INVESTOR AND MEDIA INFORMATION ONLY; NOT FOR PATIENT USE OR PROMOTIONAL PURPOSES.

 

END